The effect of low-dose and high-dose low-molecular-weight-heparin and aspirin thromboprophylaxis on clinical outcome and mortality in critical ill patients with COVID-19

References

1. 1.↵
   1. Majumder J,
   2. Minko T.

   Recent developments on therapeutic and diagnostic approaches for COVID-19. AAPS J 2021; 23: 14.

   OpenUrlCrossRefPubMedGoogle Scholar
2. 2.↵
   1. Cummings MJ,
   2. Baldwin MR,
   3. Abrams D,
   4. Jacobson SD,
   5. Meyer BJ,
   6. Balough EM, et al.

   Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet 2020; 395: 1763–1770.

   OpenUrlCrossRefPubMedGoogle Scholar
3. 3.↵
   1. Phua J,
   2. Weng L,
   3. Ling L,
   4. Egi M,
   5. Lim CM,
   6. Divatia JV, et al.

   Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. Lancet Respir Med 2020; 8: 506–517.

   OpenUrlGoogle Scholar
4. 4.↵
   1. Liu J,
   2. Liu S.

   The management of coronavirus disease 2019 (COVID-19). J Med Virol 2020; 92: 1484–1490.

   OpenUrlGoogle Scholar
5. 5.↵
   1. Asakura H,
   2. Ogawa H.

   COVID-19-associated coagulopathy and disseminated intravascular coagulation. Int J Hematol 2021; 113: 45–57.

   OpenUrlCrossRefPubMedGoogle Scholar
6. 6.↵
   1. Billett HH,
   2. Reyes-Gil M,
   3. Szymanski J,
   4. Ikemura K,
   5. Stahl LR,
   6. Lo Y, et al.

   Anticoagulation in COVID-19: effect of enoxaparin, heparin, and apixaban on mortality. Thromb Haemost 2020; 120: 1691–1699.

   OpenUrlPubMedGoogle Scholar
7. 7.↵
   1. Hanff TC,
   2. Mohareb AM,
   3. Giri J,
   4. Cohen JB,
   5. Chirinos JA.

   Thrombosis in COVID-19. Am J Hematol 2020; 95: 1578–1589.

   OpenUrlCrossRefPubMedGoogle Scholar
8. 8.↵
   1. Thachil J,
   2. Tang N,
   3. Gando S,
   4. Falanga A,
   5. Cattaneo M,
   6. Levi M, et al.

   ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020; 18: 1023–1026.

   OpenUrlCrossRefPubMedGoogle Scholar
9. 9.↵
   1. Tang N,
   2. Bai H,
   3. Chen X,
   4. Gong J,
   5. Li D,
   6. Sun Z.

   Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020; 18: 1094–1099.

   OpenUrlCrossRefPubMedGoogle Scholar
10. 10.↵
    1. Di Castelnuovo A,
    2. Costanzo S,
    3. Antinori A,
    4. Berselli N,
    5. Blandi L,
    6. Bonaccio M, et al.

    Heparin in COVID-19 Patients is associated with reduced in-hospital mortality: The Multicenter Italian CORIST Study. Thromb Haemost 2021; 121: 1054–1065.

    OpenUrlGoogle Scholar
11. 11.↵
    Turkey Republic State Health Ministry. Covid-19 (SARS-CoV-2 infection) anticytokine-anti-inflammatory treatments, coagulopathy management. [Updated 2020; accessed 2021 December 12]. Available from: https://covid19.saglik.gov.tr/Eklenti/39296/0/covid-19rehberiantisitokin-antiinflamatuartedavilerkoagulopatiyonetimipdf.pdf

    Google Scholar
12. 12.↵
    1. Schulman S,
    2. Angerås U,
    3. Bergqvist D,
    4. Eriksson B,
    5. Lassen MR,
    6. Fisher W, et al.

    Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010; 8: 202–204.

    OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
13. 13.↵
    1. Grasselli G,
    2. Greco M,
    3. Zanella A,
    4. Albano G,
    5. Antonelli M,
    6. Bellani G, et al.

    Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern Med 2020; 180: 1345–1355.

    OpenUrlGoogle Scholar
14. 14.
    1. Wichmann D,
    2. Sperhake JP,
    3. Lütgehetmann M,
    4. Steurer S,
    5. Edler C,
    6. Heinemann A, et al.

    Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med 2020; 173: 268–277.

    OpenUrlCrossRefPubMedGoogle Scholar
15. 15.↵
    1. Calabrese F,
    2. Pezzuto F,
    3. Fortarezza F,
    4. Hofman P,
    5. Kern I,
    6. Panizo A, et al.

    Pulmonary pathology and COVID-19: lessons from autopsy. The experience of European Pulmonary Pathologists. Virchows Arch 2020; 477: 359–372.

    OpenUrlCrossRefPubMedGoogle Scholar
16. 16.↵
    1. Cook D,
    2. Crowther M,
    3. Meade M,
    4. Rabbat C,
    5. Griffith L,
    6. Schiff D, et al.

    Deep venous thrombosis in medical-surgical critically ill patients: Prevalence, incidence, and risk factors. Crit Care Med 2005; 33: 1565–1571.

    OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
17. 17.↵
    1. Llitjos JF,
    2. Leclerc M,
    3. Chochois C,
    4. Monsallier JM,
    5. Ramakers M,
    6. Auvray M, et al.

    High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost 2020; 18: 1743–1746.

    OpenUrlCrossRefPubMedGoogle Scholar
18. 18.↵
    1. Meizlish ML,
    2. Goshua G,
    3. Liu Y,
    4. Fine R,
    5. Amin K,
    6. Chang E, et al.

    Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: A propensity score-matched analysis. Am J Hematol 2021; 96: 471–479.

    OpenUrlCrossRefPubMedGoogle Scholar
19. 19.↵
    1. Liu Y,
    2. Mu S,
    3. Li X,
    4. Liang Y,
    5. Wang L,
    6. Ma X.

    Unfractionated heparin alleviates sepsis-induced acute lung injury by protecting tight junctions. J Surg Res 2019; 238: 175–185.

    OpenUrlGoogle Scholar
20. 20.↵
    1. Godino C,
    2. Scotti A,
    3. Maugeri N,
    4. Mancini N,
    5. Fominskiy E,
    6. Margonato A, et al.

    Antithrombotic therapy in patients with COVID-19? -Rationale and Evidence-. Int J Cardiol 2021; 324: 261–266.

    OpenUrlPubMedGoogle Scholar
21. 21.↵
    1. Albani F,
    2. Sepe L,
    3. Fusina F,
    4. Prezioso C,
    5. Baronio M,
    6. Caminiti F, et al.

    Thromboprophylaxis with enoxaparin is associated with a lower death rate in patients hospitalized with SARS-CoV-2 infection. A cohort study. EClinicalMedicine 2020; 27: 100562.

    OpenUrlGoogle Scholar
22. 22.
    1. Yin S,
    2. Huang M,
    3. Li D,
    4. Tang N.

    Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J Thromb Thrombolysis 2021; 51: 1107–1110.

    OpenUrlGoogle Scholar
23. 23.↵
    1. Paranjpe I,
    2. Fuster V,
    3. Lala A,
    4. Russak AJ,
    5. Glicksberg BS,
    6. Levin MA, et al.

    Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol 2020; 76: 122–124.

    OpenUrlFREE Full TextGoogle Scholar
24. 24.↵
    1. Nadkarni GN,
    2. Lala A,
    3. Bagiella E,
    4. Chang HL,
    5. Moreno PR,
    6. Pujadas E, et al.

    Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19. J Am Coll Cardiol 2020; 76: 1815–1526.

    OpenUrlFREE Full TextGoogle Scholar
25. 25.
    1. Tang N,
    2. Li D,
    3. Wang X,
    4. Sun Z.

    Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18: 844–847.

    OpenUrlCrossRefPubMedGoogle Scholar
26. 26.
    1. Ferguson J,
    2. Volk S,
    3. Vondracek T,
    4. Flanigan J,
    5. Chernaik A.

    Empiric therapeutic anticoagulation and mortality in Critically Ill patients with respiratory failure from SARS-CoV-2: a retrospective cohort study. J Clin Pharmacol 2020; 60: 1411–1415.

    OpenUrlCrossRefPubMedGoogle Scholar
27. 27.↵
    1. Pesavento R,
    2. Ceccato D,
    3. Pasquetto G,
    4. Monticelli J,
    5. Leone L,
    6. Frigo A, et al.

    The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: The Padua province experience. J Thromb Haemost 2020; 18: 2629–2635.

    OpenUrlPubMedGoogle Scholar
28. 28.↵
    1. Chow JH,
    2. Khanna AK,
    3. Kethireddy S,
    4. Yamane D,
    5. Levine A,
    6. Jackson AM, et al.

    Aspirin use is associated with decreased mechanical ventilation, intensive care unit admission, and in-hospital mortality in hospitalized patients with coronavirus disease 2019. Anesth Analg 2021; 132: 930–941.

    OpenUrlGoogle Scholar
29. 29.↵
    1. Sivaloganathan H,
    2. Ladikou EE,
    3. Chevassut T.

    COVID-19 mortality in patients on anticoagulants and antiplatelet agents. Br J Haematol 2020; 190: e192–e195.

    OpenUrlPubMedGoogle Scholar
30. 30.↵
    1. Kharma N,
    2. Roehrig S,
    3. Shible AA,
    4. Elshafei MS,
    5. Osman D,
    6. Elsaid IM, et al.

    Anticoagulation in critically ill patients on mechanical ventilation suffering from COVID-19 disease, the ANTI-CO trial: A structured summary of a study protocol for a randomised controlled trial. Trials 2020; 21: 769.

    OpenUrlGoogle Scholar
31. 31.
    1. Houston BL,
    2. Lawler PR,
    3. Goligher EC,
    4. Farkouh ME,
    5. Bradbury C,
    6. Carrier M, et al.

    Anti-thrombotic therapy to ameliorate complications of COVID-19 (ATTACC): study design and methodology for an international, adaptive Bayesian randomized controlled trial. Clin Trials 2020; 17: 491–500.

    OpenUrlCrossRefPubMedGoogle Scholar
32. 32.↵
    1. Lopes RD,
    2. de Barros e Silva PGM,
    3. Furtado RHM,
    4. Macedo AVS,
    5. Ramacciotti E,
    6. Damini LP, et al.

    Randomized clinical trial to evaluate a routine full anticoagulation strategy in patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)–Coalition IV trial. Am Heart J 2021; 238: 1–11.

    OpenUrlGoogle Scholar
33. 33.↵
    1. Lopes RD,
    2. de Barros E Silva PGM,
    3. Furtado RHM,
    4. Macedo AVS,
    5. Bronhara B,
    6. Damiani LP, et al.

    Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet 2021; 397: 2253–2263.

    OpenUrlPubMedGoogle Scholar
34. 34.↵
    1. Lemos ACB,
    2. do Espírito Santo DA,
    3. Salvetti MC,
    4. Gilio RN,
    5. Agra LB,
    6. Pazin-Filho A

    , et al. Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID). Thromb Res 2020; 196: 359–366.

    OpenUrlCrossRefPubMedGoogle Scholar
35. 35.↵
    1. Jonmarker S,
    2. Hollenberg J,
    3. Dahlberg M,
    4. Stackelberg O,
    5. Litorell J,
    6. Everhov ÅH, et al.

    Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients. Crit Care 2020; 24: 1–10.

    OpenUrlCrossRefPubMedGoogle Scholar
36. 36.↵
    1. Sadeghipour P,
    2. Talasaz AH,
    3. Rashidi F,
    4. Sharif-Kashani B,
    5. Beigmohammadi MT,
    6. Farrokhpour M, et al.

    Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: The INSPIRATION Randomized Clinic. JAMA 2021; 325: 1620–1630.

    OpenUrlCrossRefPubMedGoogle Scholar
37. 37.↵
    1. Goligher EC,
    2. Bradbury CA,
    3. McVerry BJ, et al.

    REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators, Goligher EC, Bradbury CA, McVerry BJ, et al. Therapeutic anticoagulation with heparin in critically Ill patients with covid-19. N Engl J Med 2021; 385: 777–789.

    OpenUrlCrossRefPubMedGoogle Scholar
38. 38.↵
    1. Mattioli M,
    2. Benfaremo D,
    3. Mancini M,
    4. Mucci L,
    5. Mainquà P,
    6. Polenta A, et al.

    Safety of intermediate dose of low molecular weight heparin in COVID-19 patients. J Thromb Thrombolysis 2020; 51: 286–292.

    OpenUrlGoogle Scholar
39. 39.↵
    1. Musoke N,
    2. Lo KB,
    3. Albano J,
    4. Peterson E,
    5. Bhargav R,
    6. Gul F, et al.

    Anticoagulation and bleeding risk in patients with COVID-19. Thromb Res 2020; 196: 227–230.

    OpenUrlCrossRefPubMedGoogle Scholar